Fortress Biotech, Inc. (FBIO) and its majority-owned subsidiary, Cyprium Therapeutics, Inc., announced that Cyprium has entered into a definitive agreement to sell its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205 million, subject to customary closing conditions.
The PRV was issued following the U.S. FDA approval of ZUCUBO (copper histidinate, formerly known as CUTX-101) on January 12, 2026, for the treatment of Menkes disease in pediatric patients.
Cyprium had previously transferred development and commercialization rights for ZUCUBO to Sentynl Therapeutics in December 2023, while retaining eligibility for tiered royalties on net sales and up to $129 million in milestone payments. Under the agreement, Cyprium will also remit 20% of PRV sale proceeds to the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
Lindsay A.Rosenwald, M.D., Fortress' Chairman, President and CEO, highlighted the transaction as part of Fortress' ongoing execution of value-generating corporate strategies, noting three FDA approvals in the past 15 months and the recent sale of Checkpoint Therapeutics to Sun Pharma. Lung S. Yam, Cyprium's President and CEO, emphasized the approval of ZUCUBO as a milestone for Menkes disease patients and reaffirmed Cyprium's commitment to advancing its AAV-ATP7A gene therapy program.
FBIO has traded between $1.33 and $4.53 over the past year. The stock is currently trading at $4.03, up 20%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.